An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors

Epidermal growth factor receptor (EGFR) mutations identify patients with lung cancer who derive benefit from kinase inhibitors. However, most patients eventually develop resistance, primarily due to the T790M second‐site mutation. Irreversible inhibitors (e.g., osimertinib/AZD9291) inhibit T790M‐EGF...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Mol Med
Main Authors: Mancini, Maicol, Gal, Hilah, Gaborit, Nadège, Mazzeo, Luigi, Romaniello, Donatella, Salame, Tomer Meir, Lindzen, Moshit, Mahlknecht, Georg, Enuka, Yehoshua, Burton, Dominick GA, Roth, Lee, Noronha, Ashish, Marrocco, Ilaria, Adreka, Dan, Altstadter, Raya Eilam, Bousquet, Emilie, Downward, Julian, Maraver, Antonio, Krizhanovsky, Valery, Yarden, Yosef
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5801506/
https://ncbi.nlm.nih.gov/pubmed/29212784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados